Corcept Therapeutics Incorporated
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Director or officer changeSep 23 →Insiders1 insider bought $3.3M in 2 open-market buys. 8 insiders sold $40.8M, 37 of 40 sales on a 10b5-1 plan.→PeersClosest companies: VKTX, VNDA, OCUL→
From the filings
Figures
- Revenue
- $830.8Mlast 12 months
- Net income
- $55.2Mlast 12 months
- Operating cash flow
- $120.5Mlast 12 months
- Cash and equivalents
- $111.0Mat the last balance sheet
- Shares outstanding
- 106.0M shareson issue